As a result of the agreement, MammaTyper® will become part of the Sysmex Life Science portfolio in 13 territories across EMEA, including the UK, Ireland and the majority of mainland Europe.
MammaTyper® is the first real innovation in subtyping breast cancer in decades. Using RT-qPCR technology proven during the COVID-19 pandemic, the multigene test works through an easily replicated and quantitative measurement of marker gene expression, classifying each sample as a St. Gallen molecular subtype. MammaTyper® provides standardised, objective results and can also accurately assess HER2-low tumours and Ki-67 markers, offering a reliable basis for selecting the best treatment option for patients.
By being robustly reproducible, it avoids many of the common pre-analytical errors in the pathology laboratory, especially for the proliferation marker Ki-67 – critical in luminal subtyping and prognosis. Using MammaTyper® to subtype breast cancer tissue is a valuable resource for pathologists and can provide the reassurance with accurate subtyping for tailored treatment which are patient-specific.
By sharing deep scientific knowledge and an understanding of clinical needs, Sysmex Life Science and Cerca Biotech will work closely together to enable individualised breast cancer diagnostics across many markets.